Clinical rationale for administering fentanyl to cancer pain patients: Two Delphi surveys of pain management experts in Denmark

Journal of Opioid Management

Volumn 4, Issue 6, 2008, Pages 383-391

  Jacobsen, Ramune ^a   Möldrup, Claus ^a   Christrup, Lona ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Administration forms; Delphi survey; Denmark; Fentanyl; Nurses; Pain specialists; Rationale

Indexed keywords

FENTANYL;

APPLICATION SITE REACTION; ARTICLE; CANCER PAIN; CANCER PATIENT; CONSTIPATION; DELPHI STUDY; DENMARK; DRUG ADMINISTRATION ROUTE; DYSPHAGIA; HUMAN; INTERNET; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDICAL LITERATURE; MEDICAL SPECIALIST; MOUTH INJURY; NEUROPATHIC PAIN; NORMAL HUMAN; NURSE ATTITUDE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRESCRIPTION; RATING SCALE; SKIN DISEASE;

EID: 58249110566     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2008.0042     Document Type: Article

References (43)

1. Zacny JP, Lichtor JL, Zaragoza JG, et al.: Subjective and behavioral responses to intravenous fentanyl in healthy volunteers. Psychopharmacology (Berl). 1992; 107(2/3): 319-326.
2. Jeal W, Benfield P: Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs. 1997; 53(1): 109-138.
3. Fine PG, Streisand JB: A review of oral transmucosal fentanyl citrate: Potent, rapid and noninvasive opioid analgesia. J Palliat Med. 1998; 1(1): 55-63.
4. Danish Medicine Agency (Laegemiddelstyrelsen): The list of approved medicines. Available at http.//www.laegemiddelstyrelcen.dk/. Accessed December 19, 2007.
5. US Food and Drug Administration: Duragesic label. Available at http://www.fda.gov/cder/foi/label/2005/19813s0391bl.pdf. Accessed December 19, 2007.
6. US Food and Drug Administration: Medication guide actiq. Available at http.//www.fda.gov/cder/Offices/ODS/MG/fentanyl_citrateMG.pdf. Accessed December 20, 2007.
7. Mosser KH: Transdermal fentanyl in cancer pain. Am Fam Physician. 1992; 45(5): 2289-2294.
8. Southam MA: Transdermal fentanyl therapy: System design, pharmacokinetics and efficacy. Anticancer Drugs. 1995; 6(Suppl 3): 29-34.
9. Mystakidou K, Katsouda E, Tsilika E, et al.: Transdermal therapeutic fentanyl-system (TTS-F). In Vivo. 2004; 18(5): 633-642.
10. Gourlay GK: Treatment of cancer pain with transdermal fentanyl. Lancet Oncol. 2001; 2(3): 165-172.
11. Kornick CA, Santiago-Palma J, Moryl N, et al.: Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf. 2003; 26(13): 951-973.
12. Mercadante S, Fulfaro F: Alternatives to oral opioids for cancer pain. Oncology (Williston Park). 1999; 13(2): 215-225.
13. Radovanovic D, Pjevic M, Malbasa Z, et al.: The use of transdermal fentanyl in the treatment of cancer pain. Arch Oncol. 2002; 10(4): 263-266.
14. Simmonds MA, Richenbacher J: Transdermal fentanyl: Long-term analgesic studies. J Pain Symptom Manage. 1992; 7(3 Suppl): S36-S39.
15. Gordon DB: Oral transmucosal fentanyl citrate for cancer breakthrough pain: a review. Oncol Nurs Forum. 2006; 33(2): 257-264.
16. Mystakidou K, Katsouda E, Parpa E, et al.: Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: An overview of its pharmacological and clinical characteristics. J Opioid Manag. 2005; 1(1): 36-40.
17. Mystakidou K, Katsouda E, Parpa E, et al.: Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics. Drug Deliv. 2006; 13(4): 269-276.
18. Rees E: The role of oral transmucosal fetanyl citrate in the management of breakthrough cancer pain. Int J Palliat Nurs. 2002; 8(6): 304-308.
19. Zeppetella G, Ribeiro MD: Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev. 2006; 25(1): CD004311.
20. Reddy SK, Nguyen P: Breakthrough pain in cancer patients: New therapeutic approaches to an old challenge. Curr Rev Pain. 2000; 4(3): 242-247.
21. Efstathiou N, Ameen J, Coll AM: Healthcare providers' priorities for cancer care: A Delphi study in Greece. Eur J Oncol Nurs. 2007; 11(2): 141-150.
22. Møldrup C, Morgall JM: Risks of Future Drugs: A Danish Expert Delphi. Technol Forec Soc Change. 2001; 67(1): 273-289.
23. Stevens B, McGrath P, Yamada J, et al.: Identification of pain indicators for infants at risk for neurological impairment: A Delphi consensus study. BMC Pediatr. 2006; 61.
24. Akins RB, Tolson H, Cole BR: Stability of response characteristics of a Delphi panel: Application of bootstrap data expansion. BMC Med Res Methodol. 2005; 537.
25. Nevo D, Chan YE: A Delphi study of knowledge management systems: Scope and requirements. Inf Manage. 2007; 44: 538-597.
26. Bland JM, Altman DG: Cronbach's alpha. Br Med J. 1997; 314(7080): 572.
27. Fayers PM, Machin D: Quality of Life. Assessment, Analysis and Interpretation. Chichester, England: Wiley, 2007.
28. Kilner T: Educating the ambulance technician, paramedic, and clinical supervisor: Using factor analysis to inform the curriculum. Emerg Med J. 2004; 21(3): 379-385.
29. Altman DG: Practical Statistics for Medical Research. London: Chapman & Hall/CRC, 1991.
30. John Bell & Associates: Statistics for practical people. Available at http://www.proaxis.com/~johnbell/sfpp/sfpp6.htm. Accessed January 28, 2008.
31. Christrup LL, Foster D, Popper LD, et al.: Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: A randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther. 2008; 30(3): 469-481.
32. Dale O, Hjortkjaer R, Kharasch ED: Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand. 2002; 46(7): 759-770.
33. Lennernas B, Hedner T, Holmberg M, et al.: Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: A new approach to treatment of incident pain. Br J Clin Pharmacol. 2005; 59(2): 249-253.
34. Portenoy RK, Taylor D, Messina J, et al.: A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006; 22(9): 805-811.
35. Slatkin NE, Xie F, Messina J, et al.: Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol. 2007; 5(7): 327-334.
36. Zeppetella G: An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: A pilot study. J Pain Symptom Manage. 2000; 20(4): 253-258.
37. Prosser H, Walley T: New drug prescribing by hospital doctors: The nature and meaning of knowledge. Soc Sci Med. 2006; 62(7): 1565-1578.
38. Ljungberg C, Lindblad AK, Tully MP: Hospital doctors' views of factors influencing their prescribing. J Eval Clin Pract. 2007; 13(5): 765-771.
39. Powell C: The Delphi technique: Myths and realities. J Adv Nurs. 2003; 41(4): 376-382.
40. Delbecq AL, Van de Ven AH, Gustafson Ph: Group Techniques for Program Planning. A Guide to Nominal Group and Delphi Processes. Glenview, IL: Scot, Foresman and Company, 1975.
41. Sackman H: Delphi Critique. Expert Opinion, Forecasting, and Group Process. Lexington: Lexington Books, 1975.
42. Cook C, Brismee JM, Sizer PS: Factors associated with physiotherapists' confidence during assessment of clinical cervical and lumbar spine instability. Physiother Res Int. 2005; 10(2): 59-71.
43. Misener TR, Alexander JW, Blaha AJ, et al.: National Delphi study to determine competencies for nursing leadership in public health. Image J Nurs Sch. 1997; 29(1): 47-51.